Insider Selling: Simulations Plus, Inc. (NASDAQ:SLP) Director Sells 750 Shares of Stock

Simulations Plus, Inc. (NASDAQ:SLP) Director Daniel L. Weiner sold 750 shares of Simulations Plus stock in a transaction that occurred on Friday, June 28th. The stock was sold at an average price of $49.32, for a total transaction of $36,990.00. Following the completion of the sale, the director now directly owns 7,009 shares of the company’s stock, valued at approximately $345,683.88. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Simulations Plus Stock Performance

SLP opened at $39.89 on Thursday. Simulations Plus, Inc. has a fifty-two week low of $32.69 and a fifty-two week high of $52.69. The firm’s fifty day moving average is $47.68 and its 200 day moving average is $44.15. The stock has a market cap of $797.40 million, a price-to-earnings ratio of 75.26 and a beta of 0.72.

Simulations Plus (NASDAQ:SLP) last announced its quarterly earnings results on Tuesday, July 2nd. The technology company reported $0.19 EPS for the quarter, topping the consensus estimate of $0.15 by $0.04. The business had revenue of $18.54 million for the quarter, compared to analysts’ expectations of $17.92 million. Simulations Plus had a net margin of 14.36% and a return on equity of 7.80%. The business’s quarterly revenue was up 14.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.20 EPS. On average, equities research analysts predict that Simulations Plus, Inc. will post 0.55 earnings per share for the current year.

Simulations Plus Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, August 5th. Shareholders of record on Monday, July 29th will be paid a $0.06 dividend. This represents a $0.24 annualized dividend and a yield of 0.60%. The ex-dividend date is Monday, July 29th. Simulations Plus’s payout ratio is currently 45.28%.

Institutional Trading of Simulations Plus

Several hedge funds have recently bought and sold shares of the stock. Conestoga Capital Advisors LLC increased its holdings in shares of Simulations Plus by 12.5% in the 4th quarter. Conestoga Capital Advisors LLC now owns 2,259,176 shares of the technology company’s stock worth $101,098,000 after buying an additional 251,299 shares during the last quarter. Tributary Capital Management LLC bought a new stake in shares of Simulations Plus in the 4th quarter worth about $9,190,000. Ophir Asset Management Pty Ltd bought a new stake in shares of Simulations Plus in the 4th quarter worth about $7,156,000. Silvercrest Asset Management Group LLC bought a new stake in shares of Simulations Plus in the 1st quarter worth about $4,717,000. Finally, Wasatch Advisors LP increased its holdings in shares of Simulations Plus by 36.5% in the 1st quarter. Wasatch Advisors LP now owns 381,693 shares of the technology company’s stock worth $15,707,000 after buying an additional 102,135 shares during the last quarter. Hedge funds and other institutional investors own 78.08% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Craig Hallum reiterated a “buy” rating and set a $56.00 price target on shares of Simulations Plus in a research note on Wednesday. Oppenheimer lifted their target price on shares of Simulations Plus from $55.00 to $65.00 and gave the company an “outperform” rating in a research note on Thursday, June 13th. Finally, William Blair initiated coverage on shares of Simulations Plus in a research note on Friday, June 28th. They set an “outperform” rating on the stock.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.